Diabetes Mellitus, Type 1 Clinical Trial
Official title:
DiaPrecise, A Phase II Open Label Study to Evaluate the Safety and Feasibility of Intralymphatic Administration of Diamyd® in Individuals at Risk for Type 1 Diabetes Carrying the HLA DR3-DQ2 Haplotype
A 2-arm randomized Phase II Open Label Study to evaluate the safety and feasibility of intralymphatic administration of Diamyd® (Diamyd) in individuals at risk of Type 1 diabetes carrying the HLA DR3-DQ2 haplotype.
Status | Recruiting |
Enrollment | 16 |
Est. completion date | February 28, 2025 |
Est. primary completion date | February 28, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 8 Years to 18 Years |
Eligibility | Inclusion Criteria: 1. Written informed consent/assent from the individual and the individual's parents or caretaker(s) according to local regulations. 2. Males and females aged =8 and <18 years old at the time of Screening. 3. Possess the HLA DR3-DQ2 haplotype. 4. Seropositive for GADA and at least one additional T1D-associated autoantibody (IA-2A, ZnT8A or IAA). Exclusion Criteria: 1. Diagnosis of T1D (stage 3 T1D, according to the American Diabetes Association [ADA] classification). 2. Fasting glucose > 7 mmol/L (126 mg/dl), 2-hour-OGTT plasma glucose > 11.1 mmol/L (200 mg/dL) or HbA1c > 6.5% (48 mmol/mol) at the screening Visit. 3. Treatment with any anti-diabetic medication, including the use of external insulin. 4. Participation in any other clinical trial testing pharmaceutical treatments. 5. Recent (past 12 months) or current treatment with immunosuppressant therapy, including chronic use of glucocorticoid therapy. Inhaled, topical, and intranasal steroid use is acceptable. Short courses (e.g., =5 days) of oral or intra-articular injections of steroids will be permitted on trial. 6. History of hyperparathyroidism, hypercalcemia and/or nephrolithiasis, unless appropriately treated, or any other contraindication to use of Vitamin D. 7. History of epilepsy, serious head trauma or cerebrovascular accident, or clinical features of continuous motor unit activity in proximal muscles 8. Any clinically significant history of an acute reaction to a vaccine or its constituents (e.g., Alhydrogel) or lidocaine (local anesthetic) 9. Any acute or chronic skin infection or condition that would preclude intralymphatic injection. 10. Treatment with any (live or inactive) vaccine, including influenza vaccine and Coronavirus Disease 2019 (COVID-19) vaccine, within 4 weeks prior to planned first dose of study drug; or planned treatment with any vaccine up to 4 weeks after the last injection with study drug. 11. Ongoing diagnosed post-COVID19 syndrome. 12. Known diagnosis of human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection. Individuals with previous hepatitis C infection that is now cured may be eligible. 13. Any clinically significant concomitant medical condition, including but not limited to other autoimmune diseases, cardiovascular, gastrointestinal, hematological, immune, renal including a history of renal transplantation or neurological that in the opinion of the investigator would interfere with trial participation or procedures. Celiac disease with adequate diet as well as stable autoimmune thyroiditis will be permitted. 14. Any clinically significant abnormal findings detected during Screening that might jeopardize the individual's safety or ability to complete the trial. 15. Females who are lactating or pregnant (for females who have started menstruating the possibility of pregnancy must be excluded by urine ßHCG onsite prior to the study drug administration). 16. Males or females not willing to use adequate contraception, if sexually active, until 90 days after the last Diamyd administration. Adequate contraception is as follows: For females of childbearing potential (FOCBP) 1. oral (except low-dose gestagen (lynestrenol and norestisteron)), injectable, or implanted hormonal contraceptives 2. intrauterine device 3. intrauterine system (for example, progestin-releasing coil) 4. refraining from heterosexual intercourse if that is the preferred and usual lifestyle of the subject. For sexually active males 1. condom 2. Abstinence from heterosexual intercourse if that is the preferred and usual lifestyle of the subject. |
Country | Name | City | State |
---|---|---|---|
Sweden | Lund University/CRC, Skåne University Hospital, | Malmö |
Lead Sponsor | Collaborator |
---|---|
Diamyd Medical AB |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Occurrence of AEs (including Injection site reactions) and SAEs | From screening to 12 months. | ||
Primary | Number of Clinically Significant Abnormal Results from Physical examinations, including neurological and Vital Signs assessments | From screening to 12 months. | ||
Primary | Number of Clinically Significant Abnormal Results From Laboratory measurements, including hematology, clinical chemistry, metabolic status parameters (fasting C-peptide, HbA1c, fasting glucose) and urine analysis | From screening to 12 months. | ||
Secondary | Stage progression | Number of individuals progressing from stage 1 to stage 2 and from stage 2 to stage 3. | From screening to 12 months. | |
Secondary | T1D diagnosis | Time to T1D diagnosis. | From screening to 12 months. | |
Secondary | Time to stage progression | Time from stage 1 to stage 2 and time from stage 2 to stage 3. | From screening to 12 months. | |
Secondary | OGTT stimulated C-peptide | Change in C-peptide /insulin /glucose (Area Under the Curve [AUC]mean 0-120 min) during a 2-hour Oral Glucose Tolerance Test (OGTT) from screening to 12 months. | From screening to 12 months. | |
Secondary | Change in Hemoglobin A1c (HbA1c) | Change in Hemoglobin A1c (HbA1c) from baseline to 12 months. | From baseline to 12 months. | |
Secondary | Change in time in glycemic target range | Change in time in glycemic target range 3.9 to 10 mmol/L (70 to 180 mg/dL) and 3.9 to 7.8 mmol/L (70 to 140 mg/dL) evaluated from continuous glucose monitoring (CGM) data from screening to 12 months. | From screening to 12 months. | |
Secondary | Change in time in range > 13.9 mmol/L | Change in time in range > 13.9 mmol/L (> 250 mg/dL) evaluated from CGM data from screening to 12 months. | From screening to 12 months. | |
Secondary | Change in time in range > 10 mmol/L | Change in time in range > 10 mmol/L (> 180 mg/dL) evaluated from CGM data from screening to 12 months. | From screening to 12 months. | |
Secondary | Change in time in range > 7.8 mmol/L | Change in time in range > 7.8 mmol/L (> 140 mg/dL) evaluated from CGM data from screening to 12 months. | From screening to 12 months. | |
Secondary | Change in glycemic variation | Change in glycemic variation (Coefficient of variation [CV], SD) evaluated from CGM data from screening to 12 months. | From screening to 12 months. | |
Secondary | Variables that indicate effects on the immune system | Variables that indicate effects on the immune system such as the concentration of serum autoantibodies. | From baseline to 12 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Terminated |
NCT03605329 -
Evaluation of the Severity of Cardiovascular Autonomic Neuropathy in Type 1 Diabetic Patients With OSAS
|
N/A | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Recruiting |
NCT06050642 -
Study of the Impact of PROximity Support for Patients With Type 1 DIABetes Treated With an Insulin Pump or Closed Loop.
|
N/A | |
Completed |
NCT05107544 -
Metabolic, Physical Fitness and Mental Health Effects of High Intensity Interval Training (HIIT) in Adolescents With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04443153 -
Adapting Diabetes Treatment Expert Systems to Patient in Type 1 Diabetes
|
N/A | |
Completed |
NCT04521634 -
Glycaemic Variability in Acute Stroke
|
||
Completed |
NCT04569994 -
A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes
|
Phase 1 | |
Completed |
NCT04089462 -
Effects of Frequency and Duration of Exercise in People With Type 1 Diabetes A Randomized Crossover Study
|
N/A | |
Completed |
NCT03143816 -
Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study
|
Phase 4 | |
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A | |
Completed |
NCT04042207 -
Diabeloop for Highly Unstable Type 1 Diabetes
|
N/A | |
Not yet recruiting |
NCT06068205 -
COMPARATIVE ANALYSIS OF THE MORPHO-MECHANICAL PROPERTIES OF RED BLOOD CELLS EXTRACTED FROM DIABETIC PATIENTS WITH AND WITHOUT MICROVASCULAR COMPLICATIONS
|
||
Recruiting |
NCT05909800 -
Prolonged Remission Induced by Phenofibrate in Children Newly Diagnosed With Type 1 Diabetes.
|
Phase 2 | |
Active, not recruiting |
NCT04974528 -
Afrezza® INHALE-1 Study in Pediatrics
|
Phase 3 | |
Completed |
NCT04530292 -
Home Intervention and Social Precariousness in Childhood Diabetes
|
N/A | |
Completed |
NCT05428943 -
OPT101 in Type 1 Diabetes Patients
|
Phase 1 | |
Recruiting |
NCT03988764 -
Monogenic Diabetes Misdiagnosed as Type 1
|
||
Completed |
NCT05597605 -
The SHINE Study: Safety of Implant and Preliminary Performance of the SHINE SYSTEM in Diabetic Subjects
|
N/A |